Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer
Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative
About this trial
This is an interventional supportive care trial for Activating ALK Gene Mutation Negative
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed with advanced NSCLC (stage IV a-c) that are wild-type for activating genetic alterations (EGFR, ROS 1, and ALK).
- May or may not be candidates for immune checkpoint therapy.
- May have had 1-any number of prior systemic therapy regimens.
- If prior systemic regimen, must have progression disease at time of evaluation.
- Untreated brain metastases permitted.
- Completed pathological analysis of tumor tissue.
- Patients who have exhausted targeting therapy options.
- Can speak and read English.
- All participants must be willing to comply with all study procedures and be available for the duration of the study.
- Providers: Those who treat NSCLC patients as described above.
Exclusion Criteria:
• There are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. Any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.
Sites / Locations
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Arms of the Study
Arm 1
Experimental
Supportive care (treatment decision counseling session)
Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.